ID   SKM-1
AC   CVCL_0098
SY   SKM1
DR   BTO; BTO:0006520
DR   CLO; CLO_0037289
DR   EFO; EFO_0006753
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 218
DR   BioSample; SAMN03470798
DR   BioSample; SAMN03473113
DR   BioSample; SAMN10988125
DR   cancercelllines; CVCL_0098
DR   Cell_Model_Passport; SIDM00380
DR   ChEMBL-Cells; CHEMBL3308216
DR   ChEMBL-Targets; CHEMBL2366085
DR   Cosmic; 787477
DR   Cosmic; 909722
DR   Cosmic; 975300
DR   Cosmic; 1012119
DR   Cosmic; 1078731
DR   Cosmic; 1465964
DR   Cosmic; 1551462
DR   Cosmic; 2131566
DR   Cosmic; 2750855
DR   Cosmic-CLP; 909722
DR   DepMap; ACH-000373
DR   DSMZ; ACC-547
DR   DSMZCellDive; ACC-547
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 909722
DR   GEO; GSM482513
DR   GEO; GSM887581
DR   GEO; GSM888664
DR   GEO; GSM1374880
DR   GEO; GSM1446741
DR   GEO; GSM1670435
DR   GEO; GSM2124121
DR   IARC_TP53; 27238
DR   JCRB; JCRB0118
DR   JCRB; NIHS0147
DR   LiGeA; CCLE_537
DR   PharmacoDB; SKM1_1418_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0098
DR   PubChem_Cell_line; CVCL_0098
DR   Wikidata; Q54954746
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8136267;
RX   PubMed=8580805;
RX   PubMed=16408098;
RX   PubMed=20164919;
RX   PubMed=21989985;
RX   PubMed=22460905;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=27750403;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: ~48 hours (PubMed=8136267); ~48 hours (DSMZ=ACC-547).
CC   HLA typing: A*02:07,33:03; B*40:01,59:01; C*01:02,03:04; DQA1*01:02,03:02; DQB1*04:02,06:01; DRB1*04:05,08:03 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 18318; ASXL1; Simple; p.Tyr591Ter (c.1773C>A); ClinVar=VCV000451016; Zygosity=Homozygous (PubMed=27750403).
CC   Sequence variation: Mutation; HGNC; 25657; BCORL1; Simple; c.4619-1G>A; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=21989985; PubMed=27750403; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 3527; EZH2; Simple; p.Tyr646Cys (c.1937A>G); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Lys117Asn (c.351A>C); ClinVar=VCV000375965; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=27750403; Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.67%; East Asian, North=75.52%; East Asian, South=22.98%; South Asian=0%; European, North=0.33%; European, South=0.5% (PubMed=30894373).
CC   Caution: TP53 mutation indicated incorrectly as being at p.Tyr327His (c.981T>C) in PubMed=8136267.
CC   Discontinued: JCRB; NIHS0147; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): Cosmic-CLP; DSMZ; JCRB; PubMed=25877200
ST   Amelogenin: X (Cosmic-CLP; JCRB)
ST   Amelogenin: X,Y (DSMZ; PubMed=25877200)
ST   CSF1PO: 10,12
ST   D13S317: 11,13
ST   D16S539: 9,11
ST   D18S51: 14,15
ST   D19S433: 14,15
ST   D21S11: 31.2,32.2
ST   D2S1338: 19,23
ST   D3S1358: 18
ST   D5S818: 10,12
ST   D7S820: 10,11
ST   D8S1179: 11,13
ST   FGA: 22,23
ST   Penta D: 9,12
ST   Penta E: 15,19 (DSMZ)
ST   Penta E: 15,20 (PubMed=25877200)
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   NCIt; C3247; Myelodysplastic syndrome
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   76Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 40
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=8136267; DOI=10.1111/j.1365-2141.1993.tb03334.x;
RA   Nakagawa T., Matozaki S., Murayama T., Nishimura R., Tsutsumi M.,
RA   Kawaguchi R., Yokoyama Y., Hikiji K., Isobe T., Chihara K.;
RT   "Establishment of a leukaemic cell line from a patient with
RT   acquisition of chromosomal abnormalities during disease progression in
RT   myelodysplastic syndrome.";
RL   Br. J. Haematol. 85:469-476(1993).
//
RX   PubMed=8580805; DOI=10.3109/10428199509056841;
RA   Nakagawa T., Matozaki S.;
RT   "The SKM-1 leukemic cell line established from a patient with
RT   progression to myelomonocytic leukemia in myelodysplastic syndrome
RT   (MDS)-contribution to better understanding of MDS.";
RL   Leuk. Lymphoma 17:335-339(1995).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21989985; DOI=10.1182/blood-2011-05-356204;
RA   Li M., Collins R., Jiao Y.-C., Ouillette P., Bixby D., Erba H.,
RA   Vogelstein B., Kinzler K.W., Papadopoulos N., Malek S.N.;
RT   "Somatic mutations in the transcriptional corepressor gene BCORL1 in
RT   adult acute myelogenous leukemia.";
RL   Blood 118:5914-5917(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27750403; DOI=10.1002/gcc.22430;
RA   Palau A., Mallo M., Palomo L., Rodriguez-Hernandez I., Diesch J.,
RA   Campos D., Granada I., Junca J., Drexler H.G., Sole F., Buschbeck M.;
RT   "Immunophenotypic, cytogenetic, and mutational characterization of
RT   cell lines derived from myelodysplastic syndrome patients after
RT   progression to acute myeloid leukemia.";
RL   Genes Chromosomes Cancer 56:243-252(2017).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//